Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
NervGen Pharma Corp
NGENF
Primary Symbol:
V.NGEN
Healthcare
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a...
therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:NGEN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(549)
•••
deepoil0808
X
View Profile
View Bullboard History
Comment by
deepoil0808
on Mar 19, 2024 12:40pm
RE:RE:Brian Bayley sold 100,000 shares at $ 3/share
Agreed, he dumped 30% of his holdings or $ 450,000 worth of stock. That is a big chunk!!! Why would he do this? Unless..... My personal opinion,
(10)
•••
CheckingReality
X
View Profile
View Bullboard History
Comment by
CheckingReality
on Mar 19, 2024 11:38am
RE:Brian Bayley sold 100,000 shares at $ 3/share
Something is very fishy!
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(549)
•••
deepoil0808
X
View Profile
View Bullboard History
Post by
deepoil0808
on Mar 18, 2024 5:53pm
Brian Bayley sold 100,000 shares at $ 3/share
Brian Baylet sold 150,000 shares of the company: 100,000 shares from options at $ 3 per share and, 50,000 shares from his core holdings Owns +/- 333,000 shares. What prompted this big
...more
(42)
•••
greenland
X
View Profile
View Bullboard History
Post by
greenland
on Mar 18, 2024 10:38am
No comment
If insider trading was done because of a the red flag then justice will come? Nervgen Pharma Corp (NGEN-X) Insider Trade Summaries - The Globe and Mail
(549)
•••
deepoil0808
X
View Profile
View Bullboard History
Comment by
deepoil0808
on Mar 16, 2024 5:42pm
RE:Something....
Facts that observers can see the progress makes it difficult to keep a lid on results. Plunging price tells me that results do not appear to be favorable. Good Luck,
(10)
•••
CheckingReality
X
View Profile
View Bullboard History
Post by
CheckingReality
on Mar 15, 2024 12:22pm
Something....
is very wrong with this stock.
(549)
•••
deepoil0808
X
View Profile
View Bullboard History
Post by
deepoil0808
on Mar 14, 2024 4:32pm
200 day moving average $ 2.13/share
Looks like we are heading towards the 200 day moving average of $2.13 per share. Pretty steep slope so far. If it breaks this support, then it confirms that the trials may not be
...more
(549)
•••
deepoil0808
X
View Profile
View Bullboard History
Post by
deepoil0808
on Mar 13, 2024 6:07pm
Is there a leak? Drop from $ 3.80 to $ 2.89....
Trading seems to indicate a loss in confidence, Is there is leak? Good Luck
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 21, 2024 8:02am
New Press Release - NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 2023...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 20, 2024 5:37pm
New Press Release - NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - February 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 15, 2024 8:48am
New Press Release - NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning underway to make NVG-291 available to placebo-treated subjects following cohort completion Vancouver, British Columbia--(Newsfile Corp. - February 15, 2024) - NervGen...
read article.
(16)
•••
stargazer1
X
View Profile
View Bullboard History
Post by
stargazer1
on Feb 07, 2024 12:35am
We received Fast Track approval Oct. 2023, but ...
October 23, 2023) - NervGen Pharma Corporation announced today that the U.S. Food and Drug Administration has granted Fast Track designation for its proprietary lead compound, NVG-291, in individuals
...more
(3)
•••
RHertig
X
View Profile
View Bullboard History
Comment by
RHertig
on Feb 06, 2024 2:39pm
RE:Clinical trial & how it would lead to immediate approval.
Fast track is the terminology.
(16)
•••
stargazer1
X
View Profile
View Bullboard History
Post by
stargazer1
on Feb 05, 2024 4:50pm
Clinical trial & how it would lead to immediate approval.
NervGen is conducting a Phase 1a/2b clinical trial of NVG-291, which is better than a phase lll trial and could get the FDA to approve NVG-291 in short order. Previously there were: Phase
...more
(2)
•••
rdgeo44
X
View Profile
View Bullboard History
Comment by
rdgeo44
on Feb 02, 2024 7:32pm
RE:NGENF to be top biotech of 2024. Clinical trial results leak
Apart from the nice bump in the share price today, thank you for posting this article. I almost feel guilty when i look at the SP as I have a more important reason for supporting this company, that is
...more
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >